74004-74-3

Upstream product

• 75-15-0 carbon disulfide 
• 27841-33-4 4,5-dimethoxybenzene-1,2-diamine 
• 140-89-6 potassium ethyl xanthogenate 
• 7595-31-5 4-amino-5-nitroveratrol 
• 3395-03-7 4,5-dimethoxy-1,2-dinitrobenzene 
• 91-16-7 1,2-dimethoxybenzene 

Downstream Products

• 106747-01-7 2-(5,6-Dimethoxy-1H-benzoimidazol-2-ylsulfanylmethyl)-phenylamine 
• 74022-48-3 2-(γ-Dimethylaminopropylthio)-5,6-dimethoxybenzimidazole 
• 108182-02-1 5,6-dimethoxy-2-p-nitrophenacylthiobenzimidazole 
• 160006-63-3 5,6-dimethoxy-2-ethylthiobenzimidazole 
• 847504-86-3 7,8-dimethoxy-2-phenyl-4H-[1,3]thiazino[3,2-a]benzimidazol-4-ol 
• 108182-04-3 6,7-dimethoxy-3-p-nitrophenylthiazolo<3,2-a>benzimidazole 
• 106747-37-9 2-(5,6-Dimethoxy-1H-benzoimidazole-2-sulfinylmethyl)-phenylamine 

Relevant academic research and scientific papers

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier.

METHOD OF USING (H+/K+)ATPASE INHIBITORS AS ANTIVIRAL AGENTS

A class of compounds which are (H+/K+) ATPase inhibitors can be used for the treatment of viral infections. Compounds of particular interest are defined by Formula III: wherein D is N or CH; wherein R7 is one or more radicals selected from hydrido, alkoxy, amino, cyano, nitro, hydroxyl, alkyl, halo, haloalkyl, carboxyl, alkanoyl, nitro, amino, alkylamino, aminocarbonyl , aminosulfonyl , alkylaminocarbonyl, alkylcarbonylamino, alkoxycarbonyl, alkylaminosulfonyl, alkylsulfonylamino, alkylthio, alkyl-sulfinyl and alkylsulfonyl; wherein R8 is selected from hydrido, alkyl and cycloalkyl; wherein R9 is one or more radicals selected from hydrido, alkoxy, amino, alkyl, halo, cyano, nitro, hydroxyl, haloalkyl, nitro, carboxyl, alkanoyl, amino, alkylamino, dialkylamino, aminocarbonyl , alkylaminocarbonyl, alkylcarbonylamino, aminosulfonyl, alkylaminosulfonyl, alkylsulfonylamino, alkoxycarbonyl, alkylthio, alkylsulfinyl and alkylsulfonyl; and wherein R10 and R11 are independently selected from hydrido, alkyl, aryl, alkylcarbonyl and arylcarbonyl wherein the aryl ring may be further substituted with one or more radicals selected from alkyl, halo, hydrazidylcarbonyl, aminocarbonyl and alkoxy; or wherein R10 and R11 together with the nitrogen atom form a heterocyclic ring

2-[(Imidazo[1,2-a]pyridinylmethyl)sulfinyl]-1H-benzimidazoles

This invention relates to 2-[(imidazo[1,2-a]pyridinylmethyl)-sulfinyl]-1H-benzimidazoles that are useful in the treatment and prevention of ulcers.

Heterocyclic Systems Containing Brigdehead Nitrogen Atom: Part LII - Synthesis of 6,7-Dimethoxy and 5,8-Dimethoxy Thiazolobenzimidazol-3(2H)-ones, Thiazolobenzimidazoles and 2,3-Dihydrothiazolobenzimidazoles

5,6-Dimethoxy- (IIIa) and 4,7-dimethoxy-2-mercaptobenzimidazoles (IIIb), obtained by the successive reactions involving nitration of dimethoxybenzenes (Ia,b), reduction of the o-dinitrobenzenes (IIa,b) with Raney nickel and hydrazine hydrate followed by t